This news release describes a recent paper in the journal Current Biology which reports that children diagnosed with autism spectrum disorder (ASD) do not respond to unpleasant smells in the same way that other children do. Specifically, children with ASD were found not to vary their sniffing behavior regardless of whether they were presented with pleasant or unpleasant smells; whereas children without ASD would sniff less when presented with an unpleasant smell, for example. The release says that this test based on a smell — a nonverbal stimulus — could be used in very young children to diagnose the condition early, when it’s important to begin treatment. The release does a solid job of explaining this intriguing research and laying out the implications in broad terms — particularly that much additional research needs to be done before such a “sniff test” could be used in a clinical setting. The inclusion of a few more contextual details, as discussed below in the review, would have increased the value for readers as well as our star score rating for the release.
According to the CDC, in 2010 one out of every 68 children is diagnosed with ASD — so this is a subject that’s relevant to a lot families. And the CDC also says that “research shows that early intervention treatment services can greatly improve a child’s development.” But diagnosing ASD can be difficult. Given that ASD is relatively common, and that an early diagnosis may make a significant difference for children with ASD, any development that would facilitate an early diagnosis is probably worth writing about. This news release covers early stage research, but the research is interesting — and the release makes clear that significant additional work needs to be done before it could be incorporated into widespread diagnostic testing.
The release doesn’t address cost at all. And while the release notes that a so-called “sniff test” is still far from ready for clinical use, it does expressly discuss the possibility of using such a test as a diagnostic tool. We feel that if it is worth discussing a finding’s clinical application, it’s worth discussing the potential cost. We understand that it may be difficult or impossible to place a dollar value on such a diagnostic tool, but the release likely could have discussed the cost in general terms. For example, does it rely on expensive technologies or specialist skills? Or is it something that could be done by a trained general practitioner with inexpensive items? Or do we simply not know yet? Regardless, a quick sentence or two could have shed some light on the matter.
The release mentions a diagnostic accuracy rate of 81%, but where exactly does this number come from and what does the term “accuracy” mean here? We’d prefer a more detailed discussion that includes an explanation of the sensitivity and specificity of the test. Or at least a mention of false positive and false negatives. The study that’s the basis for the test told us there was 1 false positive and 6 false negatives out of the 18 people in each group. But later on in the release, we learn that the researchers aren’t sure yet if the test can distinguish between autism and other similar neurodevelopmental conditions, so the low number of false-positives reported may not hold up with additional research. In addition, the release says that while typical children adjusted their sniffing almost instantly when smelling an odor, “children on the autism spectrum showed no such response.” If that’s the case, why wasn’t the test 100% accurate?
The release did a reasonable job here and emphasized that the study isn’t ready for clinical use. But we don’t think it quite met our standard for reporting on the complex issue of diagnostic accuracy.
The problem with any diagnostic tool, including very early-stage diagnostic concepts like this one, is that while they can offer accurate diagnoses — they may also provide an inaccurate diagnosis. This is particularly relevant, since the release quotes one researcher as saying the work “raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.” But here’s the thing: in the event of a “false positive” diagnosis of ASD in a very young child, it may take months or years for the diagnosis to be disproven. That could cause unnecessary stress for the patient and family and — given the expense of ASD treatment for many families — could impose a significant economic burden as well. The damage would be minimized by using the test, as any test should be, in the context of a good clinical evaluation.
The release clearly describes the study, including the study size, the use of a control group, and the composition of the study participants. The release could have been even stronger, however, if it had placed that information in context for readers. For example, the study evaluated 18 children diagnosed with ASD and 18 children without ASD. Is that a robust sample size for a study of this kind? Most readers likely won’t know. In addition, the symptoms of autism can range from mild to severely debilitating. Where were these children on that spectrum, and what does that say about the test’s usefulness for differentiating between normal children and those with mild impairment? The release tips toward a Satisfactory rating with its emphasis on the fact the test is not ready to be used clinically. “The findings suggest that a sniff test could be quite useful in the clinic, although the researchers emphasize that their test is in no way ready for that yet.” Well said.
The release does not tell readers who funded the research. The release also doesn’t mention the fact that, as the paper itself states, “The results of this manuscript are under consideration of patent at the Weizmann Institute Office of Technology Transfer.” That’s worth mentioning, particularly since the release quotes the study’s corresponding author, who is on faculty at the Weizmann Institute of Science. This isn’t an unusual state of affairs for potentially useful research being done at large institutions, but we feel it is something that a release should share with readers.
The release infers that a new tool for early diagnosis of ASD in children would be valuable, but it doesn’t tell readers why. Readers would be better able to appreciate the significance of the new work if it had addressed — even in broad terms — the challenges involved in current approaches to diagnosing ASD. What do ASD screening and diagnostic techniques look like for infants? Toddlers? Older children? That information would be valuable context for understanding the potential importance of the new study.
The release not only makes clear that a sniff test is “in no way ready” for clinical use, but lays out several questions for relevant future research that needs to be done before such a clinical tool can be developed.
The release does mention that people with ASD have impairments in their “internal action models,” and defines these models as “templates we rely on to coordinate our senses and actions.” But, the release notes that it wasn’t previously clear “whether this impairment would show up in a test of the sniff response.” Fair enough. But researchers have published a number of papers over the years addressing various sensory differences between children with ASD and children who are developing normally (like this one, and this one, and this one). In other words, while the Current Biology paper discussed in this release is clearly new, it fits into a continuum of research on ASD and sensory sensitivity (including smell). Discussing how the new work fits into that continuum, even in a sentence or two, would have given readers valuable context.
The release did not over-sell the findings, and was very careful to point out the work that needs to be done before a clinical test can be put into widespread use.
Systematic, Criteria-Driven
Take all the issues enmeshed in any cancer screening story and amplify it with the liquid biopsy issue. @AP's @CarlaKJohnson. did a solid job here. https://apnews.com/article/science-business-health-hodgkin-lymphoma-oregon-ca899bb9c4c7f1859d4e9ce16a1cf78d
Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/
Comments (1)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Jon Brock
July 7, 2015 at 1:10 pmWhen talking about potential diagnostic tests it’s also important to consider base rates – the prevalence of the condition in the population being tested. The authors report that 12/18 autistic kids and 1/18 typically developing kids tested positive. But in real life there are 67 typically developing kids for every 1 autistic kid (according to the CDC figures). So you’d actually expect 67 false positives for every 12 true positives. In other words only 15% of positives are true positives.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like